M
Michael S. Broder
Researcher at University of California, Los Angeles
Publications - 213
Citations - 9650
Michael S. Broder is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Health care & Population. The author has an hindex of 37, co-authored 197 publications receiving 8291 citations. Previous affiliations of Michael S. Broder include American Academy of Allergy, Asthma and Immunology & University of Auckland.
Papers
More filters
Journal ArticleDOI
Impact of early detection on cancer curability: A modified Delphi panel study
Lee S. Schwartzberg,Michael S. Broder,Sikander Ailawadhi,Himisha Beltran,L. Johnetta Blakely,G. Thomas Budd,Laurie L. Carr,Michael Cecchini,Patrick W. Cobb,Anuraag R. Kansal,Ashley E. Kim,Bradley J. Monk,Deborah J.L. Wong,C. Campos,Irina Yermilov +14 more
TL;DR: The potential benefits of early cancer detection does not exist for most cancer types as mentioned in this paper , and consensus on the potential benefit of early detection is not available for most of the cancer types.
Journal ArticleDOI
Health Care Cost in Patients With Schizophrenia Treated With Brexpiprazole Versus Other Oral Atypical Antipsychotic Therapy.
Tingjian Yan,Mallik Greene,Eunice Chang,Christy R. Houle,Heidi C. Waters,Marian H. Tarbox,Michael S. Broder +6 more
TL;DR: This study compared all-cause and psychiatric inpatient hospitalization and medical costs in adult patients with SCZ newly treated with brexpiprazole versus other US Food and Drug Administration-approved OAAs in a real-world setting.
Journal ArticleDOI
Economic Burden of Neurologic Toxicities Associated with Treating Relapsed Refractory Diffuse Large B-Cell Lymphoma in the United States
Michael S. Broder,Qiufei Ma,Tingjian Yan,Eunice Chang,Lamis K. Eldjerou,Yanni Hao,David Kuzan,Jie Zhang +7 more
TL;DR: The objective of this study was to develop an evidence-based list of r/r DLBCL treatment-related neurologic adverse events (NEAEs) and to estimate the healthcare costs associated with these NEAEs in a real-world setting.
Journal ArticleDOI
Validation Of An Icd-9-Based Claims Algorithm For Identifying Patients With Chronic Idiopathic/ Spontaneous Urticaria
Karina Raimundo,B. DeCotiis,I. Hussain,S.M. Rehman,Stephen A. Tilles,N. Shahab,Marianne Eagan,Paul G. Solari,Dasha Cherepanov,E. Chang,Michael S. Broder,James L. Zazzali +11 more
Journal ArticleDOI
Effect of 21-gene recurrence score results on treatment recommendations in patients age 65 and older with lymph node-positive, estrogen receptor-positive breast cancer.
TL;DR: Results of recent Oncotype DX studies indicate that the recurrence score (RS) can identify patients with node-positive, estrogen receptor-positive (N+/ER+) breast cancer who may be at risk of recurrence.